In which year did Mobotinib officially enter medical insurance?

Mobocertinib is a targeted therapy for EGFR (epidermal growth factor receptor) mutations. It is mainly used to treat patients with non-small cell lung cancer (NSCLC), especially those with EGFR mutations. Although mobotinib has been used in the global market for a long time, the situation of mobotinib in China is different from other targeted drugs. As of now, Mobotinib has not been officially included in my country's medical insurance system, and patients need to purchase the drug through overseas channels.

Since its launch, Mobotinib has gained attention for its significant effect in the treatment of non-small cell lung cancer. However, in China, although the drug is already on the market, it has not yet been included in the coverage of medical insurance, resulting in patients having to bear higher drug costs during treatment. The purchase of Mobotinib in China is relatively complicated, and patients usually need to purchase it from abroad through special channels, so there may be a long waiting time and high logistics costs.

In overseas markets, Mobotinib is available in both original and generic versions, with certain price differences. The original drugs include the Hong Kong version and the Japanese Takeda version, and the price is about 7,000 to 8,000 yuan. In comparison, the price of generic drugs of Mobotinib is relatively affordable, especially the generic drugs from Laos. The price is only about half of the original drug, about 3,000 yuan. Although the price of generic drugs is lower, their drug ingredients are basically the same as the original drugs, so for patients, generic drugs are a more cost-effective choice.

Although mobotinib is currently not included in domestic medical insurance, patients and the medical community still hope that it will be included in medical insurance in the future to reduce the burden of treatment. Especially for those patients with non-small cell lung cancer, the efficacy of mobotinib plays an important role in disease control. As the national medical insurance policy gradually improves, more targeted therapy drugs are included in the medical insurance catalog. Mobotinib may be included in future medical insurance negotiations, thereby providing more protection for patients.

References：https://en.wikipedia.org/wiki/Mobocertinib